Fully Enrolled Pivotal APOLLOE4 Phase 3 Trial
in Early Alzheimer’s Patients on Track for Topline Data Readout in
2024
ALZ-801/Valiltramiprosate Tablet Inhibits
Formation of Soluble Toxic Amyloid Aggregates and Acts Upstream
from Late-Stage Amyloid Targeting Treatments
Robust and Sustained Plasma P-tau181 Reduction
Observed in Phase 2 Biomarker Trial, Combined with Preservation of
Brain Volume and Correlations with Cognitive Effects, Reinforces
Potential of ALZ-801 to Slow Alzheimer’s Disease Progression
ALZ-801 Safety Results in APOE4 Carriers Remain
Favorable & Consistent with Prior Formulation’s Data Resulting
in Safety Database of Over 3,000 AD Patients, Showing no Increased
Risk of Vasogenic Brain Edema
Alzheon, Inc., a clinical-stage biopharmaceutical company
developing a portfolio of product candidates and diagnostic assays
for patients suffering from Alzheimer’s disease (AD) and related
neurodegenerative disorders, today announced its participation in
the Alzheimer’s Association International Conference (AAIC) in
Philadelphia, held from July 28 to August 1, 2024.
“Our scientific presentations at this year’s AAIC conference
demonstrate our commitment to advancing Alzheimer’s research and
developing treatments that can transform the standard of care for
people living with Alzheimer’s disease,” said Susan Abushakra, MD,
Alzheon’s Chief Medical Officer. “Alzheimer’s is devastating to
patients and families, and we believe the data we are presenting
reinforce the potential of our lead agent ALZ-801/valiltramiprosate
as a first-in-class, oral disease modifying therapy that may
simplify the patient journey and provide increased access. In
addition to the presentations at AAIC, we look forward to the
upcoming topline from our pivotal APOLLOE4 Phase 3 trial later this
year. We believe these data may support ALZ-801 as the first oral
treatment to slow the progression of Alzheimer’s disease.”
Alzheon will give four presentations at the conference, which
include the following two oral sessions and two posters:
Late Breaker Podium Presentation: “Phase 3 Trial of Oral
Anti-Amyloid Agent ALZ-801/Valiltramiprosate in APOE4/4 Homozygotes
with Early Alzheimer’s Disease: Baseline Characteristics and
Prevalence of Comorbid Cerebral Amyloid Angiopathy”
- Presenter: Dr. Aidan Power, Chief Development Officer,
Alzheon Inc.
- Date and time: Wednesday, July 31, 2024: 8:00 a.m. ET –
8:45 a.m. ET
Featured Research Symposium Presentation: “Plasma
Biomarkers, Hippocampal Volume and Cognitive Effects of Oral
ALZ-801: The Phase 2 Biomarker Study and its Long-Term Extension in
APOE4 Carriers with Early Alzheimer’s Disease”
- Presenter: Dr. Susan Abushakra, Chief Medical Officer,
Alzheon Inc.
- Date and time: Wednesday, July 31, 2024: 9:00 a.m. ET –
10:30 a.m. ET
Poster: “Use of External Comparator-Arm from ADNI-1 for
the ALZ-801/Valiltramiprosate Phase 2 Study of APOE4 Carriers with
Early Alzheimer’s Disease: Regulatory Basis and Statistical
Considerations”
- Presenter: Dr. John Hey, Chief Scientific Officer,
Alzheon Inc.
- Date and time: Monday, July 29, 2024: 7:30 a.m. ET –
4:15 p.m. ET
Poster: “Low Incidence of Amyloid Related Imaging
Abnormalities over 104 Weeks in a Phase 2 Study of Amyloid
Anti-Oligomer Agent ALZ-801 (Valiltramiprosate) in Biomarker
Positive APOE4 Carriers with Early Alzheimer’s Disease”
- Presenter: Dr. Patrick Kesslak, Senior Clinical Research
Fellow
- Date and time: Tuesday, July 30, 2024: 7:30 a.m. ET –
4:15 p.m. ET
About ALZ-801 ALZ-801/valiltramiprosate is a potential
first-in-class, investigational oral agent in Phase 3 development
as a potentially disease modifying treatment for AD.1-4,6,9 ALZ‑801
is designed to block the formation of neurotoxic soluble beta
amyloid oligomers implicated in cognitive decline in Alzheimer’s
patients.1-4,6,11 In mechanism of action studies, ALZ-801 has fully
inhibited the formation of neurotoxic soluble beta amyloid
oligomers at the Phase 3 clinical dose.6,9,11 ALZ‑801 acts through
a novel enveloping molecular mechanism of action to block formation
of neurotoxic soluble amyloid oligomers in the human brain11
associated with the onset and progression of cognitive decline in
AD patients.1,4,6,7 ALZ-801 received Fast Track designation from
the U.S. Food and Drug Administration in 2017 for Alzheimer’s
disease. In clinical trials, ALZ-801 has shown potential for robust
clinical efficacy and favorable safety results with no increased
risk of brain vasogenic edema.2-7,10,12 The initial Phase 3 program
for ALZ-801 is focusing on Early AD patients with two copies of the
apolipoprotein ε4 allele (APOE4/4 homozygotes), with potential
future program expansion to AD treatment and prevention in patients
carrying one copy of the APOE4 gene and noncarriers.1–7
ALZ-801 Phase 2 Biomarker Trial Biomarker Effects of
ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
(NCT04693520): This ongoing trial was designed to evaluate the
effects of 265 mg twice daily oral dose of ALZ-801 on biomarkers of
AD pathology in subjects with Early AD, who have either the APOE4/4
or APOE3/4 genotype and constitute 65-70% of Alzheimer's patients.
The trial also included evaluation of clinical efficacy, safety,
tolerability, and pharmacokinetic profile of ALZ-801 over 104 weeks
of treatment (primary endpoint). An ongoing long-term extension of
the trial evaluates ALZ-801 for an additional 104 weeks of
treatment for a total of 208 weeks.
ALZ-801 APOLLOE4 Phase 3 Trial An Efficacy and Safety
Study of ALZ-801 in APOE4/4 Early Alzheimer's Disease Subjects
(NCT04770220): This ongoing trial is designed to evaluate the
efficacy, safety, biomarker and imaging effects of 265 mg twice
daily oral dose of ALZ-801 in Early AD subjects with two copies of
the apolipoprotein ε4 allele (APOE4/4 homozygotes), who constitute
approximately 15% of Alzheimer's patients. This is a double-blind,
randomized trial comparing oral ALZ-801 to placebo treatment over
78 weeks. The APOLLOE4 trial is supported by a $51 million grant
from the National Institute on Aging.
ALZ-801 APOLLOE4 Long Term Extension Trial An ongoing
long-term extension of the trial, APOLLOE4-LTE, evaluates ALZ-801
in subjects who complete the core APOLLOE4 study for an additional
52 weeks of treatment for a total of 130 weeks or 2.5 years over
the core and LTE study (NCT06304883).
About Alzheon Alzheon, Inc. is a clinical-stage
biopharmaceutical company developing a broad portfolio of product
candidates and diagnostic assays for patients suffering from
Alzheimer’s disease and other neurodegenerative disorders. We are
committed to developing innovative medicines by directly addressing
the underlying pathology of neurodegeneration. Our lead Alzheimer’s
clinical candidate, ALZ-801/valiltramiprosate, is a first-in-class
oral agent in Phase 3 development as a potentially disease
modifying treatment for AD. ALZ-801 is an oral small molecule that
has been observed to fully block the formation of neurotoxic
soluble amyloid oligomers in preclinical tests. Our clinical
expertise and technology platform are focused on developing drug
candidates and diagnostic assays using a precision medicine
approach based on individual genetic and biomarker information to
advance therapies with the greatest impact for patients.
Alzheon Scientific Publications 1 Tolar M, et al: The
Single Toxin Origin of Alzheimer’s Disease and Other
Neurodegenerative Disorders Enables Targeted Approach to Treatment
and Prevention, International Journal of Molecular Sciences,
2024; 25, 2727. 2 Hey J, et al: Analysis of Cerebrospinal Fluid,
Plasma β‑Amyloid Biomarkers, and Cognition from a 2‑Year Phase 2
Trial Evaluating Oral ALZ‑801/Valiltramiprosate in APOE4 Carriers
with Early Alzheimer’s Disease Using Quantitative Systems
Pharmacology Model, Drugs 2024. 3 Hey J, et al: Effects of
Oral ALZ‑801/Valiltramiprosate on Plasma Biomarkers, Brain
Hippocampal Volume, and Cognition: Results of 2‑Year Single‑Arm,
Open‑Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s
Disease, Drugs 2024. 4 Tolar M, et al: Neurotoxic Soluble
Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a
Clinically Validated Target for Slowing Disease Progression,
International Journal of Molecular Sciences, 2021; 22, 6355.
5 Abushakra S, et al: APOE ε4/ε4 Homozygotes with Early Alzheimer’s
Disease Show Accelerated Hippocampal Atrophy and Cortical Thinning
that Correlates with Cognitive Decline, Alzheimer’s &
Dementia, 2020; 6: e12117. 6 Tolar M, et al: Aducanumab,
Gantenerumab, BAN2401, and ALZ-801—the First Wave of
Amyloid-Targeting Drugs for Alzheimer’s Disease with Potential for
Near Term Approval, Alzheimer’s Research & Therapy,
2020; 12: 95. 7 Tolar M, et al: The Path Forward in Alzheimer’s
Disease Therapeutics: Reevaluating the Amyloid Cascade Hypothesis,
Alzheimer’s & Dementia, 2019; 1-8. 8 Hey JA, et al:
Discovery and Identification of an Endogenous Metabolite of
Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid
Oligomer Formation in the Human Brain, CNS Drugs, 2018;
32(9): 849-861. 9 Hey JA, et al: Clinical Pharmacokinetics and
Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development
for the Treatment of Alzheimer’s Disease, Clinical
Pharmacokinetics, 2018; 57(3): 315–333. 10 Abushakra S, et al:
Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients
with Mild Alzheimer’s Disease Suggest Disease Modification
Potential, Journal of Prevention of Alzheimer’s Disease,
2017; 4(3): 149-156. 11 Kocis P, et al: Elucidating the Aβ42
Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s
Disease: Integrating Molecular Analytical Methods, Pharmacokinetic
and Clinical Data, CNS Drugs, 2017; 31(6): 495-509. 12
Abushakra S, et al: Clinical Benefits of Tramiprosate in
Alzheimer’s Disease Are Associated with Higher Number of APOE4
Alleles: The “APOE4 Gene-Dose Effect,” Journal of Prevention of
Alzheimer’s Disease, 2016; 3(4): 219-228.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723403529/en/
Media Contact Nate Greene, Alzheon, Inc. 401.487.4390
nate.greene@alzheon.com
Investor Contact Erwan de Naurois, Alzheon, Inc.
802.735.8789 erwan.denaurois@alzheon.com